- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04442113
RandOmised Controlled Trial of STAR Mapping™ Guided Ablation for AF. (ROC-STAR)
Multicenter Randomized Controlled Trial Assessing Targeted Ablation in Persistent Atrial Fibrillation Using the Stochastic Trajectory Analysis of Ranked Signals (STAR Mapping™) Method.
Study Overview
Status
Conditions
Detailed Description
This will be a prospective multi-centre randomised controlled trial with two treatment arms. We plan to include up to 15 UK centres. Patients that have been referred for catheter ablation of symptomatic persistent AF will be recruited. Patients will be consented and have their baseline review after having been listed for AF ablation on the hospital waiting list. They will be randomized to one of two treatment arms. All patients will undergo their procedure using a 3D mapping system. Standard catheters will be used during the ablation procedure. Because the STAR mapping™ system will be configured for use with a special version of the 3D mapping system Carto (BIosense Webster) the study will mandate use of clinically approved Carto catheters: Smarttouch thermocool ablation catheter and the Pentarray mapping catheter. Ablation procedures will be carried out using the usual policies and protocols of the institutions involved except for the specific points below. The two treatment arms include:
- Control arm - PVI alone After PVI, no further ablation in AF will be allowed. If the patient organizes into an atrial tachycardia (AT) during PVI this will be mapped and ablated. Otherwise, in accordance with common clinical practice, a 30 minute waiting period will be observed following PVI to watch for acute pulmonary vein reconnection. During this waiting period, mapping data will be acquired using the multipolar pulmonary vein mapping catheter to acquire STAR mapping™ data. The operator will be blinded to these data. This is done using the pentarray mapping catheter to acquire a minimum of 10 widely spaced globally distributed left atrial recordings of 30 seconds each outside the pulmonary veins. If the patient has remained in AF post PVI then electrical cardioversion will be performed, the pulmonary veins checked and re-isolated if needed, and the procedure terminated.
- Experimental arm - PVI followed by STAR guided ablation. If the patient organises to sinus rhythm after PVI alone then a 30 minute wait will be observed to ensure sustained PVI and the procedure terminated. If patients remain in AF following PVI, the left atrium will be mapped using a multipolar mapping catheter to acquire a minimum of 10 widely spaced globally distributed recordings outside the pulmonary veins. STAR mapping™ data will be exported and maps generated. Ablation will then be targeted at the leading sites identified by STAR mapping™ in order of ranking (1st first, 2nd second, etc.) with the end-point of AF termination. If AF terminates further sites will not be targeted. If patients terminate to an atrial tachycardia then this will be mapped and ablated as per standard clinical practice.
If AF persists following ablation of all STAR mapping™ identified sites then mapping of the right atrium may be considered if the septum consistently activates early and the coronary sinus activation is predominantly proximal to distal, and further ablation permitted in the right atrium if indicated. If patients remain in AF following ablation then they will be electrically cardioverted.
Follow-up All patients will undergo 12 months follow-up with an ECG at 3, 6, 9 and 12 months, and a 48h ambulatory Holter monitor at 6 and 12 months. Patients will routinely continue anti-arrhythmic therapy for up to 3 months post procedure which will be considered a blanking period. After 3 months rhythmically active antiarrhythmic drugs will be stopped.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Persistent AF (continuous AF duration between 1 week and 24 months)
- No previous AF ablation or other left atrial ablation
- Undergoing a clinical AF ablation procedure.
Exclusion Criteria:
- Unwillingness to sign consent
- Any other contraindication to catheter ablation
- Age <18 years or > 80 years
- AF with a reversible cause
- AF that is paroxysmal
- AF that has been persistent > 2 yrs
- Previous left atrial ablation (percutaneous or surgical)
- Severe LV impairment (EF < 40%)
- NYHA class 3 or 4 heart failure
- Severely dilated left atrium (LA diameter > 50 mm)
- Known cardiomyopathy or inherited 'channelopathy'
- Congential heart disease (excluding PFO)
- More than moderate valvular heart disease or prosthetic heart valves
- Prior MI, PCI or cardiac surgery in the last 6 months
- Pregnancy
- Morbid obesity (defined as BMI >40)
- Any other medical problem likely to cause death within the next 18 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Control group
Pulmonary vein isolation alone (by catheter ablation)
|
Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)
|
EXPERIMENTAL: STAR guided ablation group
Pulmonary vein isolation plus ablation guided by STAR MappingTM
|
Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the proportion of subjects in the 2 groups with clinical success
Time Frame: 12 months
|
Clinical success is defined as freedom from atrial arrhythmia (AF or atrial tachycardia) lasting >30 seconds after a single procedure off antiarrhythmic drugs subsequent to a 3 month blanking period (standard guideline definition of clinical success).
|
12 months
|
Comparison of the proportion of subjects in the 2 groups with termination of AF during ablation
Time Frame: During the index procedure (i.e. day 0)
|
Termination of AF during ablation
|
During the index procedure (i.e. day 0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the proportion of subjects in the 2 groups with major complications following their index procedure.
Time Frame: 30 days
|
major complications are defined as any complication causing death, disability, results in another intervention, or prolongs hospital stay (as per guidelines).
|
30 days
|
Comparison of the proportion of subjects in the 2 groups with early failure following their index procedure.
Time Frame: 3 months
|
Early failure is described as recurrent AF or atrial tachycardia at the 3 months time point.
|
3 months
|
Comparison of the proportion of subjects in the 2 groups reaching a composite electrophysiological end point during their index procedure
Time Frame: During the index ablation procedure (i.e. day 0)
|
The composite electrophysiological end point is comprised of either AF termination or slowing of AF cycle length ≥30ms measured from the left atrial appendage during ablation.
|
During the index ablation procedure (i.e. day 0)
|
Radiofrequency ablation time
Time Frame: Intraprocedural
|
Duration of radiofrequency ablation
|
Intraprocedural
|
Procedure time
Time Frame: Intraprocedural
|
Duration of procedure
|
Intraprocedural
|
Comparison of the proportion of subjects in the 2 groups with freedom from AF
Time Frame: 12 months
|
Freedom from AF defined as no documented AF (>30 seconds) following the 3 months blanking period following a single procedure, off anti-arrhythmic drugs.
|
12 months
|
Comparison of the proportion of subjects in the 2 groups with freedom from atrial arrhythmia allowing for antiarrhythmic drugs.
Time Frame: 12 months
|
Freedom from documented atrial arrhythmia (>30 seconds) following the 3 months blanking period following a single procedure, allowing for anti-arrhythmic drugs.
|
12 months
|
Comparison of the proportion of subjects in the 2 groups with freedom from AF allowing for antiarrhythmic drugs
Time Frame: 12 months
|
Freedom from AF defined as no documented AF (>30 seconds) following the 3 months blanking period following a single procedure, allowing for anti-arrhythmic drugs.
|
12 months
|
Relationship between the number of AF drivers identified using STAR mapping™ and clinical outcome
Time Frame: 12 months
|
The number of AF drivers identified will be correlated to the proportion of patients with clinical success at 1 year (the primary end-point).
This analysis will be performed for all 177 patients, and for each of the 2 groups separately.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Honarbakhsh S, Hunter RJ, Finlay M, Ullah W, Keating E, Tinker A, Schilling RJ. Development, in vitro validation and human application of a novel method to identify arrhythmia mechanisms: The stochastic trajectory analysis of ranked signals mapping method. J Cardiovasc Electrophysiol. 2019 May;30(5):691-701. doi: 10.1111/jce.13882. Epub 2019 Mar 5.
- Honarbakhsh S, Hunter RJ, Ullah W, Keating E, Finlay M, Schilling RJ. Ablation in Persistent Atrial Fibrillation Using Stochastic Trajectory Analysis of Ranked Signals (STAR) Mapping Method. JACC Clin Electrophysiol. 2019 Jul;5(7):817-829. doi: 10.1016/j.jacep.2019.04.007. Epub 2019 May 8.
- Honarbakhsh S, Schilling RJ, Finlay M, Keating E, Ullah W, Hunter RJ. STAR mapping method to identify driving sites in persistent atrial fibrillation: Application through sequential mapping. J Cardiovasc Electrophysiol. 2019 Dec;30(12):2694-2703. doi: 10.1111/jce.14201. Epub 2019 Oct 3.
- Honarbakhsh S, Schilling RJ, Keating E, Finlay M, Hunter RJ. Drivers in AF colocate to sites of electrogram organization and rapidity: Potential synergy between spectral analysis and STAR mapping approaches in prioritizing drivers for ablation. J Cardiovasc Electrophysiol. 2020 Jun;31(6):1340-1349. doi: 10.1111/jce.14456. Epub 2020 Apr 9.
Helpful Links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROC-STAR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Maastricht UniversityRadboud University Medical Center; Maastricht University Medical CenterRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation ParoxysmalNetherlands
Clinical Trials on Pulmonary vein isolation
-
University of LeipzigRecruiting
-
University Medical Center GroningenBoston Scientific CorporationNot yet recruiting
-
Instituto de investigación e innovación biomédica...Active, not recruitingAtrial Fibrillation, PersistentSpain
-
Brigham and Women's HospitalBoston Scientific CorporationNot yet recruitingAtrial Fibrillation, Paroxysmal or PersistentUnited States
-
Hospital General Universitario de AlicanteNot yet recruiting
-
AtriCure, Inc.Active, not recruitingAtrial FibrillationUnited States
-
Asklepios proresearchCompletedAtrial Fibrillation | TachycardiaGermany
-
Diagram B.V.CompletedParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Out of Range Hypertension | Signs of Sympathetic OverdriveSpain, Netherlands
-
Haukeland University HospitalUniversity Hospital of North Norway; St. Olavs HospitalCompletedPersistent Atrial FibrillationNorway
-
Hospital Clinic of BarcelonaRecruiting